WASHINGTON — In his quest to bring down drug prices, President Trump has advocated for policy proposals that the pharmaceutical industry opposes, including importing drugs from Canada. But his new health secretary pick — who, if confirmed, would immediately have the authority to kick-start some importation — has firmly rejected the idea.

Alex Azar spent 10 years defending the pharmaceutical industry and its pricing tactics as he rose through the ranks at the Indianapolis-based pharmaceutical giant Eli Lilly. Like many in the industry, he reframes questions about drug prices to focus on the importance of generic competition or the power of insurance companies to lower a consumer’s out-of-pocket exposure.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hi Erin – I should have introduced myself to you at the discussion with Ed and Dr. Woodcock on Monday! Here’s some food for thought. Azar writes: “These drugs are not American-produced drugs sitting in a Canadian retail pharmacy.” But I assume he knows that most medications sitting in American retail pharmacies are not “American-produced.” It’s a canard that we can’t do importation safely because we already do. We just released some data that showed 70% of popularly prescribed brand name drugs (IMS Health, top 40, 2015) sold in the U.S. are foreign made: https://www.pharmacychecker.com/news/fda-understates-percentage-of-foreign-made-medication-sold-in-us.asp. Many of those FDA-approved medications are safely sold in other countries at much lower cost.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy